SQLite Web: event_store.db

Update row 1210 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-07T23:23:54.391414+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:ec007e35dcb85562","evidence_event_ids":["evt_6db821ca434c"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","as_of":"2026-04-07T23:23:54.391414+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","company":"SANGAMO THERAPEUTICS, INC","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","article_chars":3618,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_bfe0f6b1c5e57a87","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","content_type":"text/plain","enriched_at":"2026-04-07T23:51:22.842021+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","source_event_id":"evt_6db821ca434c","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"d7a4e9175419ed7a","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-06","2026-01-22","2026-02-24","2026-02-25","2025-11-28","2025-11-29","2025-05-30","2025-02-25","2024-11-29","2024-05-31","2024-02-25","2023-11-30","2023-05-31","2022-05-31","2022-02-25","2021-05-31","2021-04-30","2021-10-30","2020-10-30"],"entities":[{"asset_class":"equity","name":"Sangamo Therapeutics, Inc","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"equity","name":"Nathalie Dubois-Stringfellow","relevance":"high","symbol":"","type":"reporting-owner_officer"},{"asset_class":"other","name":"Nasdaq","relevance":"medium","symbol":"","type":"exchange"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal text (no prior Form 144 state or diff details included).","The filing\u2019s specific resale quantity, share class details beyond \u201cNasdaq Common Stock,\u201d and any \u201caggregate amount\u201d fields are not explicitly shown in the provided cleaned text.","No explicit statement of whether the shares are being sold immediately vs over a period is included in the provided excerpt."],"key_facts":["SEC accession number: 0001947007-26-000008.","Form type: 144; filed as of date: 20260406; date as of change: 20260406.","Subject company/issuer: SANGAMO THERAPEUTICS, INC (CIK 0001001233).","Reporting-entity name: Nathalie Dubois-Stringfellow (officer).","Security described as: Nasdaq Common Stock.","Filing includes a sequence of transactions dated 10/30/2020 through 02/25/2026, including ESPP purchases (cash) and RSU vesting settled in stock (consideration described as continued service).","Signature: /s/ Nathalie Dubois-Stringfellow; dated 04/06/2026."],"numeric_claims":[{"label":"Form 144 filed as of date","value":"2026-04-06"},{"label":"Accession number","value":"0001947007-26-000008"},{"label":"Reporting-entity CIK (Nathalie Dubois-Stringfellow)","value":"0001947007"},{"label":"Issuer CIK","value":"0001001233"}],"primary_claim":"On 2026-04-06, SANGAMO THERAPEUTICS, INC filed Form 144 (accession 0001947007-26-000008) for resale of Nasdaq common stock by officer Nathalie Dubois-Stringfellow.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Sangamo Therapeutics, Inc. filed a Form 144 on 2026-04-06 for resale of shares by reporting-entity officer Nathalie Dubois-Stringfellow. The filing lists multiple prior stock transactions (ESPP purchases and RSU vesting settled in stock) and indicates the shares are Nasdaq common stock.","topics":["SEC Form 144","insider resale","common stock","ESPP","RSU vesting","officer transactions"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 SANGAMO THERAPEUTICS, INC \u00b7 Filed 20260406","ticker":"SGMO","tickers":["SGMO"],"title":"SGMO filed 144","url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel